We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

50 hedge funds and large institutions have $21.9M invested in Tempest Therapeutics in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

6% more funds holding

Funds holding: 47 → 50 (+3)

21% less capital invested

Capital invested by funds: $27.9M → $21.9M (-$5.97M)

62% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 13

Holders
50
Holders Change
+3
Holders Change %
+6.38%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
5
Reduced
13
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.1M
2
Deutsche Bank
Deutsche Bank
Germany
+$734K
3
BCM
Bridgeway Capital Management
Texas
+$575K
4
LCM
Laurion Capital Management
New York
+$474K
5
Two Sigma Investments
Two Sigma Investments
New York
+$348K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$4.99M
2
ACA
Avoro Capital Advisors
New York
-$1.59M
3
GC
GMT Capital
Georgia
-$1.14M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$562K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$365K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$5M -$562K -134 -10%
Jennison Associates
2
Jennison Associates
New York
$3.06M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.82M -$327K -78 -15%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$1.79M – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$1.09M +$1.1M +263 +6,575%
Franklin Resources
6
Franklin Resources
California
$890K – – –
SM
7
Sabby Management
Florida
$840K +$71.3K +17 +9%
BC
8
Broadfin Capital
New York
$770K – – –
Deutsche Bank
9
Deutsche Bank
Germany
$724K +$734K +175 +8,750%
BlackRock
10
BlackRock
New York
$647K +$4.2K +1 +0.6%
BCM
11
Bridgeway Capital Management
Texas
$560K +$575K +137 New
TS
12
Third Security
Virginia
$523K – – –
LCM
13
Laurion Capital Management
New York
$461K +$474K +113 New
Millennium Management
14
Millennium Management
New York
$407K -$164K -39 -28%
BCM
15
BBT Capital Management
Texas
$355K – – –
Two Sigma Investments
16
Two Sigma Investments
New York
$342K +$348K +83 New
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$341K -$365K -87 -51%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$300K -$21K -5 -6%
AIC
19
AWM Investment Company
New York
$210K – – –
Wells Fargo
20
Wells Fargo
California
$209K -$46.2K -11 -18%
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$195K +$201K +48 New
DMK
22
David M. Knott
$157K -$37.8K -9 -19%
JP Morgan Chase
23
JP Morgan Chase
New York
$127K +$130K +31 New
ERSOT
24
Employees Retirement System of Texas
Texas
$124K – – –
Squarepoint
25
Squarepoint
New York
$122K +$126K +30 New
1
2 3

TPST Hedge Fund Activity: Q4 2017 in Review

50 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2017, worth a combined $21.9M — down 21% from $27.9M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TPST positions and 10 closed out — a net gain of 3 holders — while 5 added to existing stakes and 13 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.1M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.99M sold.

  • 50 institutional investors held Tempest Therapeutics (TPST) as of Q4 2017, up from 47 in Q3 2017.
  • Funds reported $21.9M of Tempest Therapeutics stock for Q4 2017, down 21% quarter-over-quarter.
  • 13 funds opened new Tempest Therapeutics positions in Q4 2017 and 10 closed out, a net change of +3 holders.
  • The largest Tempest Therapeutics buyer in Q4 2017 was Renaissance Technologies, an estimated $1.1M added.
  • The largest Tempest Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $4.99M sold.

Based on aggregated 13F filings for Q4 2017.